Zevra Therapeutics, Inc.ZVRANASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+72.8%
5Y CAGR+57.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+72.8%/yr
vs +4.7%/yr prior
5Y CAGR
+57.8%/yr
Recent acceleration
Acceleration
+68.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
9.8x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$77.62M+41.5%
2024$54.87M+56.4%
2023$35.09M+133.3%
2022$15.04M+72.8%
2021$8.70M+9.8%
2020$7.92M-26.8%
2019$10.82M-13.5%
2018$12.51M-2.1%
2017$12.77M-8.8%
2016$14.00M-